2,368 results
P
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy
I/C
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy
O
Excess weight loss, Type 2 diabetes mellitus resolution, Postoperative complication and reoperation rates, Dyslipidemia, Hypertension, Gastroesophageal reflux disease
P
Oral anticoagulants (OAC), P-glycoprotein (P-gp)/CYP3A4 enzyme
I/C
P-gp/CYP3A4 inhibitors, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Warfarin
O
Major bleeding, Gastrointestinal (GI) bleeding, Stroke/systemic embolism (SE), All-cause mortality, Any bleeding, Intracranial hemorrhage (ICH)
P
soil microbial extracellular hydrolytic enzymatic activities (Hy-EEAs), soil oxidative enzymatic activities (Ox-EEAs), soil carbon (C), soil nitrogen (N), soil phosphorus (P)
I/C
natural forest conversion (NFC), Changes in soil Hy- and Ox-EEAs, changes in soil organic C, available P, microbial biomass C and N
O
depletion of soil organic carbon, stimulated soil microbial secretion of Hy- and Ox-EEAs, soil total N scarcity, provoke soil microbial Hy-EEAs, soil total P dearth, quickened the soil Ox-EEAs, plenitude of soil available P, suppressed soil Hy- and Ox-EEAs
P
patients with advanced cancer
I/C
receiving immune checkpoint inhibitors (ICIs), sarcopenia vs. no sarcopenia
O
response rate, 1-y progression-free survival (PFS) rate, 1-y overall survival (OS) rate, hazard ratios (HRs) of PFS and OS
P
monolithic translucent Y-TZP ceramics
I/C
hydrothermal aging, aged Y-TZP ceramics
O
translucency parameter (TP), L*
P
patients with type 2 diabetes (T2D) and overweight or obesity
I/C
Roux-en-Y gastric bypass (RYGB), medical therapy
O
T2D remission, achieving American Diabetes Association's (ADA's) treatment goal
P
NSCL/P patients, controls
I/C
MTHFR A1298C polymorphism, allele, homozygote, heterozygote, dominant, and recessive models
O
association between A1298C polymorphism and NSCL/P risk
P
patients undergoing total gastrectomy for gastric cancer
I/C
J-pouch (JP) reconstruction, standard Roux-en-Y (RY) esophagojejunostomy
O
dumping syndrome, heartburn symptoms
P
prostate cancer patients
I/C
high-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT), IDC-P and without IDC-P
O
oncological outcomes, including biochemical recurrence-free survival (BCRFS) and clinical progression-free survival (CPFS)
P
patients with cervical spondylotic myelopathy (CSM)
I/C
Zero profile intervertebral fusion system (Zero-P), traditional anterior plate cage system (PC)
O
postoperative dysphagia, avoiding ALOD, ASD, screw loosening